Biotech-CEO:”It’s the offer of the day - pure and simple.”
A computer-modelling of the toxicology of pharmaceuticals could shorten the preclinical phase considerably and be a huge help to especially start-up companies.
In a world in which risk willing capital isn’t as willing as it used to be, it is highly important – especially to start-up companies – to have the sustainability of their business idea confirmed as early as possible.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
